It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis arteriosclerosis such as those resulting from diabetes dyslipidemia hypercholesterolemia lipid-related diseases inflammatory diseases that are caused by inflammatory cytokines skin diseases such as allergic skin diseases diabetes or Alzheimers disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate:(wherein, each V and W independently show N or C-R7 each X and Y independently show CH2, C=O, SO2, etc. Z shows CH or N each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc. R3 shows C1-8 alkyl group R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group R5 and R6 show a hydrogen atom, etc. L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc. and n shows any integer of 0 to 2.)
